BioWave, a new pain relief device produced by UK-based medtech firm Platform-14, has been awarded a CE mark, making the technology available for use in Europe, the Middle East and Africa.

Despite more than two fifths of the UK population suffering from chronic pain, new NICE guidance on managing chronic pain offered little in the way of solutions for those living with it, with little support available on the NHS.

BioWave could potentially be used to treat chronic pain. The device utilises high-frequency conduction to block and relieve pain at its source. According to a clinical trial involving 428 patients, 84 per cent of those involved felt their pain significantly reduced after using the device.

Platform-14 founder Steve Dechan commented: “We are delighted that BioWave has secured a CE mark and is now available for use in the UK. There are millions of adults living with Chronic Pain in the UK, with the NHS offering no solution for them beyond exercise and opioid pain relief.”

“BioWave has the potential to revolutionise the chronic pain landscape, offering patients and the NHS a safe and effective drug-free solution.”

Dr Dominic Hegarty, President-elect of the World Institute of Pain, said: “Chronic Pain can be a debilitating and life changing condition. However, despite millions living with Chronic Pain throughout the UK, the condition is little understood and options for treatment for those living with pain are limited and often insufficient. BioWave is an effective, reliable and affordable pain therapy that has the potential to improve the lives of pain sufferers throughout the UK.”

Contact us


Tel: +44 (0)1424 777745

Fax: +44 (0)1424 777746



Kirkham Young Ltd.
The Old Court House
North Trade Road
East Sussex
TN33 0EX